187 related articles for article (PubMed ID: 19903456)
1. AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Choi JS; Park C; Jeong JW
Biochem Biophys Res Commun; 2010 Jan; 391(1):147-51. PubMed ID: 19903456
[TBL] [Abstract][Full Text] [Related]
2. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
3. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
4. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
Aoki E; Yano R; Yokoyama H; Kato H; Araki T
Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
[TBL] [Abstract][Full Text] [Related]
5. Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease model.
Choi JS; Lee MS; Jeong JW
Biochem Biophys Res Commun; 2010 Apr; 394(3):854-8. PubMed ID: 20307492
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells.
Mathiasen JR; McKenna BA; Saporito MS; Ghadge GD; Roos RP; Holskin BP; Wu ZL; Trusko SP; Connors TC; Maroney AC; Thomas BA; Thomas JC; Bozyczko-Coyne D
Brain Res; 2004 Apr; 1003(1-2):86-97. PubMed ID: 15019567
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease.
Zhang D; Anantharam V; Kanthasamy A; Kanthasamy AG
J Pharmacol Exp Ther; 2007 Sep; 322(3):913-22. PubMed ID: 17565007
[TBL] [Abstract][Full Text] [Related]
9. Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF-kappaB in MPTP-treated mice: implication in Parkinson's disease.
Karunakaran S; Ravindranath V
J Neurochem; 2009 Jun; 109(6):1791-9. PubMed ID: 19457134
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
Knyihár-Csillik E; Csillik B; Pákáski M; Krisztin-Péva B; Dobó E; Okuno E; Vécsei L
Neuroscience; 2004; 126(4):899-914. PubMed ID: 15207325
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Kreisler A; Gelé P; Wiart JF; Lhermitte M; Destée A; Bordet R
Brain Res; 2007 Mar; 1135(1):77-84. PubMed ID: 17196944
[TBL] [Abstract][Full Text] [Related]
12. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
Tripanichkul W; Sripanichkulchai K; Finkelstein DI
Brain Res; 2006 Apr; 1084(1):28-37. PubMed ID: 16564034
[TBL] [Abstract][Full Text] [Related]
13. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse.
Przybyłkowski A; Kurkowska-Jastrzebska I; Joniec I; Ciesielska A; Członkowska A; Członkowski A
Brain Res; 2004 Sep; 1019(1-2):144-51. PubMed ID: 15306248
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation.
Li R; Peng N; Du F; Li XP; Le WD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Apr; 26(4):376-80. PubMed ID: 16624731
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
19. A cell-permeable peptide inhibitor TAT-JBD reduces the MPP+-induced caspase-9 activation but does not prevent the dopaminergic degeneration in substantia nigra of rats.
Pain S; Barrier L; Deguil J; Milin S; Piriou A; Fauconneau B; Page G
Toxicology; 2008 Jan; 243(1-2):124-37. PubMed ID: 18037221
[TBL] [Abstract][Full Text] [Related]
20. Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expression.
Brown JM; Gouty S; Iyer V; Rosenberger J; Cox BM
J Neurochem; 2006 Jul; 98(2):495-505. PubMed ID: 16749908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
